Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: Progress report on the MRC AML 10 trial

R. F. Stevens; I. M. Hann; K. Wheatley; R. Gray; O. B. Eden; C. C. Bailey; P. R.H. Barbor; A. Barrett; C. Barton; V. Broadbent; J. M. Chessells; P. Derbyshire; S. I. Dempsey; J. Durrant; B. Gibson; F. G.H. Hill; J. Kernahan; J. S. Lilleyman; J. Mann; J. Martin; S. T. Mellor; P. Morris Jones; A. Oakhill; J. Peto; M. Redford; J. K.H. Rees; S. M. Richards; G. P. Summerfield; E. Thompson

Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: Progress report on the MRC AML 10 trial

R. F. Stevens, I. M. Hann, K. Wheatley, R. Gray, O. B. Eden, C. C. Bailey, P. R.H. Barbor, A. Barrett, C. Barton, V. Broadbent, J. M. Chessells, P. Derbyshire, S. I. Dempsey, J. Durrant, B. Gibson, F. G.H. Hill, J. Kernahan, J. S. Lilleyman, J. Mann, J. MartinS. T. Mellor, P. Morris Jones, A. Oakhill, J. Peto, M. Redford, J. K.H. Rees, S. M. Richards, G. P. Summerfield, E. Thompson

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

The Medical Research Council's AML 10 Children Trial commenced in 1988. It is a multicentre collaberative study based on 4 courses of intensive chemotherapy with additional allogeneic bone marrow transplantation for children with a matched sibling donor. The remaining children are randomised either to an autologous transplant using unpurged marrow or stopping therapy. To date 156 eligible patients have been entered with a CR rate of 91%. 56% of children are still alive 2 years after trial entry and 57% are in CR 3 years after achieving CR. The treatment regimen is intensive but mortality and morbidity are acceptable. The study will need to accrue patients for a further 2 to 3 years in the hope of defining the role of allogeneic and autologous marrow transplantation.

Original language	English
Pages (from-to)	55-58
Number of pages	4
Journal	Leukemia
Volume	6
Issue number	SUPPL. 2
Publication status	Published - Jun 1992

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Stevens, R. F., Hann, I. M., Wheatley, K., Gray, R., Eden, O. B., Bailey, C. C., Barbor, P. R. H., Barrett, A., Barton, C., Broadbent, V., Chessells, J. M., Derbyshire, P., Dempsey, S. I., Durrant, J., Gibson, B., Hill, F. G. H., Kernahan, J., Lilleyman, J. S., Mann, J., ... Thompson, E. (1992). Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: Progress report on the MRC AML 10 trial. Leukemia, 6(SUPPL. 2), 55-58.

@article{72b448ff5d6446fbbe52379002bc297a,

title = "Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: Progress report on the MRC AML 10 trial",

abstract = "The Medical Research Council's AML 10 Children Trial commenced in 1988. It is a multicentre collaberative study based on 4 courses of intensive chemotherapy with additional allogeneic bone marrow transplantation for children with a matched sibling donor. The remaining children are randomised either to an autologous transplant using unpurged marrow or stopping therapy. To date 156 eligible patients have been entered with a CR rate of 91%. 56% of children are still alive 2 years after trial entry and 57% are in CR 3 years after achieving CR. The treatment regimen is intensive but mortality and morbidity are acceptable. The study will need to accrue patients for a further 2 to 3 years in the hope of defining the role of allogeneic and autologous marrow transplantation.",

author = "Stevens, {R. F.} and Hann, {I. M.} and K. Wheatley and R. Gray and Eden, {O. B.} and Bailey, {C. C.} and Barbor, {P. R.H.} and A. Barrett and C. Barton and V. Broadbent and Chessells, {J. M.} and P. Derbyshire and Dempsey, {S. I.} and J. Durrant and B. Gibson and Hill, {F. G.H.} and J. Kernahan and Lilleyman, {J. S.} and J. Mann and J. Martin and Mellor, {S. T.} and {Morris Jones}, P. and A. Oakhill and J. Peto and M. Redford and Rees, {J. K.H.} and Richards, {S. M.} and Summerfield, {G. P.} and E. Thompson",

year = "1992",

month = jun,

language = "English",

volume = "6",

pages = "55--58",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "SUPPL. 2",

}

Stevens, RF, Hann, IM, Wheatley, K, Gray, R, Eden, OB, Bailey, CC, Barbor, PRH, Barrett, A, Barton, C, Broadbent, V, Chessells, JM, Derbyshire, P, Dempsey, SI, Durrant, J, Gibson, B, Hill, FGH, Kernahan, J, Lilleyman, JS, Mann, J, Martin, J, Mellor, ST, Morris Jones, P, Oakhill, A, Peto, J, Redford, M, Rees, JKH, Richards, SM, Summerfield, GP & Thompson, E 1992, 'Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: Progress report on the MRC AML 10 trial', Leukemia, vol. 6, no. SUPPL. 2, pp. 55-58.

TY - JOUR

T1 - Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML

T2 - Progress report on the MRC AML 10 trial

AU - Stevens, R. F.

AU - Hann, I. M.

AU - Wheatley, K.

AU - Gray, R.

AU - Eden, O. B.

AU - Bailey, C. C.

AU - Barbor, P. R.H.

AU - Barrett, A.

AU - Barton, C.

AU - Broadbent, V.

AU - Chessells, J. M.

AU - Derbyshire, P.

AU - Dempsey, S. I.

AU - Durrant, J.

AU - Gibson, B.

AU - Hill, F. G.H.

AU - Kernahan, J.

AU - Lilleyman, J. S.

AU - Mann, J.

AU - Martin, J.

AU - Mellor, S. T.

AU - Morris Jones, P.

AU - Oakhill, A.

AU - Peto, J.

AU - Redford, M.

AU - Rees, J. K.H.

AU - Richards, S. M.

AU - Summerfield, G. P.

AU - Thompson, E.

PY - 1992/6

Y1 - 1992/6

N2 - The Medical Research Council's AML 10 Children Trial commenced in 1988. It is a multicentre collaberative study based on 4 courses of intensive chemotherapy with additional allogeneic bone marrow transplantation for children with a matched sibling donor. The remaining children are randomised either to an autologous transplant using unpurged marrow or stopping therapy. To date 156 eligible patients have been entered with a CR rate of 91%. 56% of children are still alive 2 years after trial entry and 57% are in CR 3 years after achieving CR. The treatment regimen is intensive but mortality and morbidity are acceptable. The study will need to accrue patients for a further 2 to 3 years in the hope of defining the role of allogeneic and autologous marrow transplantation.

AB - The Medical Research Council's AML 10 Children Trial commenced in 1988. It is a multicentre collaberative study based on 4 courses of intensive chemotherapy with additional allogeneic bone marrow transplantation for children with a matched sibling donor. The remaining children are randomised either to an autologous transplant using unpurged marrow or stopping therapy. To date 156 eligible patients have been entered with a CR rate of 91%. 56% of children are still alive 2 years after trial entry and 57% are in CR 3 years after achieving CR. The treatment regimen is intensive but mortality and morbidity are acceptable. The study will need to accrue patients for a further 2 to 3 years in the hope of defining the role of allogeneic and autologous marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0026772225&partnerID=8YFLogxK

M3 - Article

C2 - 1578942

AN - SCOPUS:0026772225

SN - 0887-6924

VL - 6

SP - 55

EP - 58

JO - Leukemia

JF - Leukemia

IS - SUPPL. 2

ER -

Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: Progress report on the MRC AML 10 trial

Abstract

ASJC Scopus subject areas

UN SDGs

Fingerprint

Cite this